Comparison of Epidural Labor Analgesia With Dexmedetomidine or Sufentanil

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-15

Study Completion Date

2020-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The participants: 1800 full-term primiparas will be selected with ASA I-Ⅱgrade, 20 to 35 years old and weighing 55 to 90 kg in the investigator's hospital from may 2018 to December 2018. 1200 primiparas were divided into A and B according to the computer randomized numbers, and 600 parturients without labor analgesia in the same period were selected as group C, with 600 patients in each group. All parturients signed the informed consent form and were approved by the hospital ethics Committee.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine-Ropivacine Versus Sufentanil-Ropivacaine for Epidural Labor Analgesia

NCT05698407

Pregnancy Related

COMPLETED PHASE4

Effect of Sufentanil and Ropivacaine

NCT02488291

Anesthesia Complications

COMPLETED NA

Dexmedetomidine-esketamine-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia

NCT07145775

Epidural Analgesia Labor Pain Sufentanil +3 more

NOT_YET_RECRUITING PHASE4

Onset of Labour Epidural Analgesia With Different Concentration Bupivacaine and Different Doses of Sufentanyl

NCT03395600

Pregnant Women Who Requested Epidural Analgesia in the Early Stage of Labor

COMPLETED PHASE4

Epidural Dexmedetomidine vs Nalbuphine for Labor Analgesia

NCT05327088

Epidural Anesthesia Labor Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1200 primiparas were divided into A and B according to the computer randomized numbers, and 600 parturients without labor analgesia in the same period were selected as group C, with 600 patients in each group. All parturients signed the informed consent form and were approved by the hospital ethics Committee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacological Action

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine ropivacaine

Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.

Intervention Type DRUG

No analgesia labor

No analgesia labor control group

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sufentanil ropivacaine No analgesia labor control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA I-Ⅱ, aged 22 - 42,
* gestational age ≥ 37, weight 55 - 90 kg,
* labor analgesia is required by full-term primiparas.

Exclusion Criteria

* serious cardiovascular and cerebrovascular system diseases,
* bradycardia, conduction block
* fetal distress
* contraindications of intraspinal anesthesia.

Minimum Eligible Age

22 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No